Allogene Therapeutics (NYSE: ALLO) — Perfil da empresa, notícias e dados financeiros
Allogene Therapeutics pioneers AlloCAR T™ therapies for cancer, targeting both hematologic malignancies and solid tumors.
Allogene Therapeutics
Allogene Therapeutics (NASDAQ:ALLO) is a biotechnology company focused on pioneering and advancing allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. With a robust pipeline of investigational therapies in various stages of development, Allogene aims to harness the power of the immune system to target and eradicate cancer cells. Their projects span across multiple cancer types, including both hematologic malignancies and solid tumors, with the objective of delivering transformative, readily available treatments. By leveraging cutting-edge technology and scientific research, Allogene is dedicated to improving patient outcomes and providing new hope in the fight against cancer.
Resumo
Operações
Produtos e/ou serviços de Allogene Therapeutics
- AlloCAR T therapy for cancer, leveraging engineered T-cells to target and eliminate tumor cells.
- Partnership on UCART19, an off-the-shelf CAR T-cell therapy for acute lymphoblastic leukemia.
- Advancements in AlloJoin for knee osteoarthritis, using allogeneic chondrocyte implantation techniques.
- Development of ALLO-715, aimed at treating multiple myeloma through a novel CAR T-cell approach.
- ALLO-501 and ALLO-501A, targeting non-Hodgkin's lymphoma with next-generation CAR T-cell therapies.
- Research into solid tumor treatments, exploring CAR T-cell strategies against traditionally challenging cancer types.
equipe executiva do Allogene Therapeutics
- Arie S. BelldegrunCo-Founder & Executive Chairman
- Zachary J. RobertsPresident, CEO & Director
- Joshua A. KazamCo-Founder & Director
- David D. ChangCo-Founder & Director
- Geoffrey M. ParkerExecutive VP & CFO
- Annie YoshiyamaSenior VP of Finance, Corporate Controller & Principal Accounting Officer
- Benjamin M. BeneskiSenior VP & Chief Technical Officer
- Earl M. DouglasSenior VP, General Counsel, Compliance Officer & Corporate Secretary
- Susan R. LundeenChief People Officer
- Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer
Últimas notícias sobre a Allogene Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Allogene Therapeutics, em USD.
- Cap. de mercado
- 425 mi
- Receita (TTM)
- 4,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -206,9 mi | -190,9 mi | |
| 22 mil | -273,2 mi | -257,6 mi | |
| 95 mil | -327,7 mi | -327,3 mi | |
| 243 mil | -335,4 mi | -329,8 mi |